Skip to content

The clinical efficacy and brain plasticity mechanism research of acupuncture for patients with moderate depression: a randomized controlled trial

The clinical efficacy and brain plasticity mechanism research of acupuncture for patients with moderate depression: a randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029915
Enrollment
Unknown
Registered
2020-02-16
Start date
2020-02-17
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate depression

Interventions

Sponsors

Guangdong Provincial Hospital of Tradition Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Aged range 18-50 years, male or female, right handed; (2) Met the diagnosis criteria of depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); (3) Hamilton Depression Scale (HAMD-24) score is 27-35 (Moderate depression); (4) No medical treatment, physical and psychological therapy more than 3 weeks or maintain stable medical treatment at least 3 weeks; (5) People who volunteer to participate in this study and sign the written informed consent.

Exclusion criteria

Exclusion criteria: (1) History of self harm or suicide; (2) History of schizophrenia, bipolar disorder or severe personality disorder; (3) History of alcohol abuse or drug dependence; (4) History of severe traumatic brain injury or epilepsy; (5) Participants who have serious cardiovascular diseases, liver diseases or kidney diseases; (6) People who refuse acupuncture treatment during the trial; (7) Metal implant in skull or pacemaker; (8) Women in pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
HAMD-24;

Secondary

MeasureTime frame
BDI;Motor evoked potentials (MEPs);The resting motor threshold (rMT);Contralateral silent period (CSP);Rating Scale for Side Effects (SERS);

Countries

China

Contacts

Public ContactJianhua Liu
jyhf08@sina.com+86 13729889452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026